NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
Clinical Trials
19 trialsNCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT00006669 2021-10-27
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Medstar Health Research Institute
Phase 2 Withdrawn
NCT02605694 2021-03-17
FRESCO
SecuraBio
Phase 2 Withdrawn
NCT02538926 2018-11-14
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Withdrawn
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT02702960 2018-06-15
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01087580 2017-03-03
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT00598858 2016-12-08
2007-5904
University of California, Irvine
Phase 2 Withdrawn
NCT01539174 2016-03-03
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT01670084 2015-10-30
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
Phase 2 Withdrawn
NCT00004039 2015-08-19
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn
NCT02159690 2015-01-26
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Phase 2 Withdrawn
NCT01814865 2013-12-20
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT01750866 2013-10-16
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01478308 2013-03-06
Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT00811031 2012-07-30
Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn